TUKYSA™ (tucatinib) for the treatment of HER2-Positive Breast Cancer
TUKYSA exhibits anti-tumour activity in HER2 expressing tumour cells. Credit: Business Wire
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more